- Admitting that the HCV therapy world has leapfrogged its interferon-based faldaprevir, Boehringer Ingelheim decides to stop development of hepatitis C therapies. It will withdraw all pending marketing applications worldwide.
- Related tickers: (GILD +0.4%) (ABBV -0.7%) (BMY -0.2%) (MRK +0.9%)
One member of Big Pharma bids adieu to HCV
Recommended For You
About GILD Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| GILD | - | - |
| Gilead Sciences, Inc. | ||